167 related articles for article (PubMed ID: 36405757)
21. Radiotherapy-activated NBTXR3 nanoparticles modulate cancer cell immunogenicity and TCR repertoire.
Darmon A; Zhang P; Marill J; Mohamed Anesary N; Da Silva J; Paris S
Cancer Cell Int; 2022 Jun; 22(1):208. PubMed ID: 35659676
[TBL] [Abstract][Full Text] [Related]
22. RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer.
Ahern E; Harjunpää H; O'Donnell JS; Allen S; Dougall WC; Teng MWL; Smyth MJ
Oncoimmunology; 2018; 7(6):e1431088. PubMed ID: 29872559
[TBL] [Abstract][Full Text] [Related]
23. Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.
Vijayakumar G; McCroskery S; Palese P
J Virol; 2020 Jan; 94(3):. PubMed ID: 31694938
[TBL] [Abstract][Full Text] [Related]
24. Peripheral PD1-positive CD4 T-Lymphocyte Count Can Predict Progression-free Survival in Patients With Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitor.
Inomata M; Kado T; Okazawa S; Imanishi S; Taka C; Kambara K; Hirai T; Tanaka H; Tokui K; Hayashi K; Miwa T; Hayashi R; Matsui S; Tobe K
Anticancer Res; 2019 Dec; 39(12):6887-6893. PubMed ID: 31810958
[TBL] [Abstract][Full Text] [Related]
25. Carbon ion irradiation plus CTLA4 blockade elicits therapeutic immune responses in a murine tumor model.
Hartmann L; Osen W; Eichmüller OL; Kordaß T; Furkel J; Dickes E; Reid C; Debus J; Brons S; Abdollahi A; Moustafa M; Rieken S; Eichmüller SB
Cancer Lett; 2022 Dec; 550():215928. PubMed ID: 36183858
[TBL] [Abstract][Full Text] [Related]
26. NBTXR3, a first-in-class radioenhancer for pancreatic ductal adenocarcinoma: Report of first patient experience.
Bagley AF; Ludmir EB; Maitra A; Minsky BD; Li Smith G; Das P; Koong AC; Holliday EB; Taniguchi CM; Katz MHG; Tamm EP; Wolff RA; Overman MJ; Patel S; Kim MP; Tzeng CD; Ikoma N; Bhutani MS; Koay EJ
Clin Transl Radiat Oncol; 2022 Mar; 33():66-69. PubMed ID: 35097226
[TBL] [Abstract][Full Text] [Related]
27. Durable Responses to Anti-PD1 and Anti-CTLA4 in a Preclinical Model of Melanoma Displaying Key Immunotherapy Response Biomarkers.
Shklovskaya E; Pedersen B; Stewart A; Simpson JOG; Ming Z; Irvine M; Scolyer RA; Long GV; Rizos H
Cancers (Basel); 2022 Oct; 14(19):. PubMed ID: 36230753
[TBL] [Abstract][Full Text] [Related]
28. Thyroid Immune-Related Adverse Events in Patients with Cancer Treated with anti-PD1/anti-CTLA4 Immune Checkpoint Inhibitor Combination: Clinical Course and Outcomes.
Lui DTW; Lee CH; Tang V; Fong CHY; Lee ACH; Chiu JWY; Leung RCY; Kwok GGW; Li BCW; Cheung TT; Woo YC; Lam KSL; Yau T
Endocr Pract; 2021 Sep; 27(9):886-893. PubMed ID: 33581327
[TBL] [Abstract][Full Text] [Related]
29. NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2-3, randomised, controlled trial.
Bonvalot S; Rutkowski PL; Thariat J; Carrère S; Ducassou A; Sunyach MP; Agoston P; Hong A; Mervoyer A; Rastrelli M; Moreno V; Li RK; Tiangco B; Herraez AC; Gronchi A; Mangel L; Sy-Ortin T; Hohenberger P; de Baère T; Le Cesne A; Helfre S; Saada-Bouzid E; Borkowska A; Anghel R; Co A; Gebhart M; Kantor G; Montero A; Loong HH; Vergés R; Lapeire L; Dema S; Kacso G; Austen L; Moureau-Zabotto L; Servois V; Wardelmann E; Terrier P; Lazar AJ; Bovée JVMG; Le Péchoux C; Papai Z
Lancet Oncol; 2019 Aug; 20(8):1148-1159. PubMed ID: 31296491
[TBL] [Abstract][Full Text] [Related]
30. Optimal Irreversible Electroporation Combined with Nano-Enabled Immunomodulatory to Boost Systemic Antitumor Immunity.
Peng W; Cao Y; Zhang Y; Zhong A; Zhang C; Wei Z; Liu X; Dong S; Wu J; Xue Y; Wu M; Yao C
Adv Healthc Mater; 2024 Mar; 13(7):e2302549. PubMed ID: 38059737
[TBL] [Abstract][Full Text] [Related]
31. First-in-Human Study Testing a New Radioenhancer Using Nanoparticles (NBTXR3) Activated by Radiation Therapy in Patients with Locally Advanced Soft Tissue Sarcomas.
Bonvalot S; Le Pechoux C; De Baere T; Kantor G; Buy X; Stoeckle E; Terrier P; Sargos P; Coindre JM; Lassau N; Ait Sarkouh R; Dimitriu M; Borghi E; Levy L; Deutsch E; Soria JC
Clin Cancer Res; 2017 Feb; 23(4):908-917. PubMed ID: 27998887
[No Abstract] [Full Text] [Related]
32. Local and Targeted Delivery of Immune Checkpoint Blockade Therapeutics.
Han X; Li H; Zhou D; Chen Z; Gu Z
Acc Chem Res; 2020 Nov; 53(11):2521-2533. PubMed ID: 33073988
[TBL] [Abstract][Full Text] [Related]
33. Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy.
Rose AAN; Armstrong SM; Hogg D; Butler MO; Saibil SD; Arteaga DP; Pimentel Muniz T; Kelly D; Ghazarian D; King I; Kamil ZS; Ross K; Spreafico A
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33483342
[TBL] [Abstract][Full Text] [Related]
34. Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with anti-PD1 in pancreatic cancer.
Carbone C; Piro G; Agostini A; Delfino P; De Sanctis F; Nasca V; Spallotta F; Sette C; Martini M; Ugel S; Corbo V; Cappello P; Bria E; Scarpa A; Tortora G
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34479922
[TBL] [Abstract][Full Text] [Related]
35. High Plus Low Dose Radiation Strategy in Combination with TIGIT and PD1 Blockade to Promote Systemic Antitumor Responses.
Barsoumian HB; Sezen D; Menon H; Younes AI; Hu Y; He K; Puebla-Osorio N; Wasley M; Hsu E; Patel RR; Yang L; Cortez MA; Welsh JW
Cancers (Basel); 2022 Jan; 14(1):. PubMed ID: 35008385
[TBL] [Abstract][Full Text] [Related]
36. Association of immune-checkpoint inhibitors and the risk of immune-related colitis among elderly patients with advanced melanoma: real-world evidence from the SEER-Medicare database.
Almutairi AR; Slack M; Erstad BL; McBride A; Abraham I
Ther Adv Drug Saf; 2021; 12():2042098621991279. PubMed ID: 33796257
[TBL] [Abstract][Full Text] [Related]
37. Analysis of the Abscopal Effect With Anti-PD1 Therapy in Patients With Metastatic Solid Tumors.
Ribeiro Gomes J; Schmerling RA; Haddad CK; Racy DJ; Ferrigno R; Gil E; Zanuncio P; Buzaid AC
J Immunother; 2016; 39(9):367-372. PubMed ID: 27741091
[TBL] [Abstract][Full Text] [Related]
38. Immune checkpoint therapy for non-small-cell lung cancer: an update.
Xia B; Herbst RS
Immunotherapy; 2016; 8(3):279-98. PubMed ID: 26860624
[TBL] [Abstract][Full Text] [Related]
39. DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma.
Fitzgerald AA; Wang S; Agarwal V; Marcisak EF; Zuo A; Jablonski SA; Loth M; Fertig EJ; MacDougall J; Zhukovsky E; Trivedi S; Bhatia D; O'Neill V; Weiner LM
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34737215
[TBL] [Abstract][Full Text] [Related]
40. PI3Kαδ Inhibitor Combined With Radiation Enhances the Antitumor Immune Effect of Anti-PD1 in a Syngeneic Murine Triple-Negative Breast Cancer Model.
Chang WI; Han MG; Kang MH; Park JM; Kim EE; Bae J; Ahn S; Kim IA
Int J Radiat Oncol Biol Phys; 2021 Jul; 110(3):845-858. PubMed ID: 33642128
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
